The Ministry of Food and Drug Safety (MFDS, Minister Yu-Kyoung Oh) announced on the 20th that it has approved the orphan drug Vyvgart(efgartigimod alfa) for the treatment of adult patients with general myasthenia gravis (gMG) who are anti-AChR antibody positive.

Myasthenia gravis is an autoimmune disease characterized by decreased neuromuscular signaling and generalized muscle weakness caused by IgG (Immunoglobulin G) autoantibodies that target components of the neuromuscular junction.

Vyvgart Inj works by preventing the binding of autoantibody IgG to the neonatal Fc receptor (FcRn)*, which promotes the degradation of autoantibodies, bringing therapeutic benefit in patients with aut